| 1.36 0.01 (0.74%) | 09-06 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.94 | 1-year : | 1.07 |
| Resists | First : | 0.8 | Second : | 0.92 |
| Pivot price | 0.69  |
|||
| Supports | First : | 0.61 | Second : | 0.51 |
| MAs | MA(5) : | 0.66  |
MA(20) : | 0.69 |
| MA(100) : | 1.15 |
MA(250) : | 2.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.6 |
D(3) : | 23.7 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 11.48 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BVXV ] has closed above bottom band by 39.1%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.65 - 0.66 | 0.66 - 0.66 |
| Close: | 0.66 - 0.67 | 0.67 - 0.67 |
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Mon, 11 Sep 2023
Press Release Distribution and Management - GlobeNewswire
Wed, 06 Sep 2023
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of ... - GlobeNewswire
Tue, 11 Jul 2023
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals ... - Yahoo Finance
Wed, 21 Dec 2022
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax ... - AccessWire
Thu, 30 Dec 2021
BiondVAX Pharmaceuticals Ltd. (NASDAQ: BVXV) Enters Definitive Agreements To Develop And Commercialize novel ... - BP Journal
Sat, 27 Mar 2021
BVXV: Phase 3 Data for Universal Flu Vaccine in Late September to Late October 2020… - Zacks Small Cap Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 20 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -2.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | -0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|